PORTLAND, Ore. (January 6, 2016)—According to a new report by Allied Market Research, titled, "World Continuous Glucose Monitoring (CGM) Systems—Market Opportunities and Forecasts, 2014–2021," the global continuous glucose monitoring market would generate revenue of $2,930 million by 2021, registering a CAGR of 31.3 percent from 2015 to 2021. CGM sensors accounted for about two-third share of the global CGM components market in 2014 and will continue to dominate the market until 2021.
The need of active management and control of diabetes has grown considerably with the growing diabetic population and associated cost burden. It is projected that by 2035 the diabetes-affected patient population will reach 471 million with an associated cost burden of $627 billion. Continuous monitoring and managing glucose levels is an essential factor in diabetes management, which is primarily delivered by CGMs.
Many high-tech variants of CGMs have evolved such as smartphone-connected CGMs, wearable CGMs and non-invasive CGMs. The improved efficacy and high disease prevalence has brought these devices to center stage of glucose monitoring. Increasing awareness, FDA approval of novel and innovative products such as the bionic pancreas, and focus on developing CGM devices to serve new end user segments are prime drivers to the growth of CGM market. However, lack of an adequate reimbursement regimen for devices and clinicians, has been the key barrier to the adoption of the devices.
Sensors led the market for CGM components and are also the fastest growing segment. This growth is primarily supplemented by recurring sales, high frequency of use, bulk purchasing and the limited life of sensors. Integrated insulin pumps have emerged as a lucrative market segment over the forecast period.
CGMs have proved to be an extremely effective tool for glucose monitoring in Critical Care/Intensive Care Units (ICUs). Many healthcare regulatory authorities across developed and developing regions have imposed Tight Glycemic Control (TGC) protocols. Mandatory TGC protocols in ICUs will render hospitals a lucrative market for CGMs by 2020. The need for POC/OTC CGMs will result in the emergence of home health care as the second most lucrative customer segment in the CGM market.
Key findings of the study:
- The North American CGM market will continue to lead CGM market throughout the forecast period, majorly due to the sustained payers' access, better affordability and increasing confidence of CGMs among dialectologists
- The ever-growing demand for POC/OTC CGM will enable home health care to be the second-most lucrative end user-segment
- The Gen X demographic segment is the highly amenable for usage of CGMs
- The UK CGM market will register a CAGR of 40.9 percent during the forecast period
Europe will also be a lucrative market segment, as the certification approval process in Europe is faster and relatively easier as compared to FDA approval in the US. However, the Asian-Pacific region is projected to register the fastest growth, mainly due to a large patient pool and rapid penetration of CGMs in emerging markets. China is quickly becoming the "diabetes capital" of the world. Consequently, companies such as Medtronic and Dexcom have already expanded their distribution and supply networks in China. The enhanced supply-side infrastructure and large patient base, along with increasing purchasing power, would collectively make China CGM market to be the most lucrative within the Asian-Pacific region.
The key companies profiled in the report are Abbott, Animas, Dexcom, Glysens, Insulet, Medtronic, Omnipod, Roche, Senseonics and Yposomed.
Find the full report here.
